吡柔比星组胺类物质检查法建立的可行性考察被引量：4

Feasibility Study on Test Method Establishment for Histamine-like Substances in Pirarubicin

下载PDF

导出

摘要目的:建立吡柔比星的组胺类物质检查法。方法:按2010年版《中国药典》化学药品注射剂安全性检查法应用指导原则中的组胺类物质检查法进行试验。结果:该品种在0.01 mg·ml^(-1)浓度下对组胺类物质检查无干扰作用;运用建立的方法对10批样品进行组胺类物质检查,结果与降压物质检查法一致。结论:所建立的吡柔比星的组胺类物质检查方法具有可行性,其组胺类物质检查限值可定为1μg·mg^(-1)。 Objective： To establish the test method for histamine-like substances in pirarubicin. Methods： According to the method described in the appendix of Chinese Pharmacopoeia （2010 edition）, the test for histamine-like substances was carried out. Resuits： The test for histamine-like substances had no interference under the condition with pirarubicin concentration of 0.01 mg· ml-l. The established test method for histamine-like substances in pirarubicin was applied in 10 samples, and the results were accordant with those of the test method for depressor substances. Conclusion： The test method for histamine-like substances in pirarubicin is feasible -1 with the limit of 1 μg ·mg

作者鲁艺冼静雯陈润桦秦美蓉王晓炜王平

机构地区深圳药品质量标准研究重点实验室深圳市药品检验所

出处《中国药师》 CAS 2016年第2期402-405,共4页 China Pharmacist

关键词吡柔比星组胺类物质检查法 Pirarubicin Histamine-like substances Test

分类号 R927.11 [医药卫生—药学]

引文网络
相关文献

参考文献5

1王方彤,庄镇华,等.吡柔比星的药理和毒理研究[J].肿瘤研究与临床,2002,14(6):427-429. 被引量：6
2国家药典委员会.国家药品标准工作手册[s].2013年版.234,264.
3何忠平,方远书,李爱玲,裘颖儿,尤卫民,吴韶铭.浙江省实验用猫寄生虫感染情况调查分析[J].山东畜牧兽医,2010,31(5):90-91. 被引量：6
4进口药品注册标准[S].JX20020287.
5中国药典[S].二部.2010.

二级参考文献20

1Umezawa H, Takahashi Y, Kinoshita M,et al. Tetrahydropyranyl derivatives of daunomycin and adriamycin [J]. J Antibiotics, 1979,32:1082—1084.
2Nguyen H N,Sevin B U,Averette H,et al. Comparative evaluation of pirarubicin and adriamycin in gynecologic cancer cell lines [J]. Gynecol Oncol, 1992, 45 (2):164—173.
3Hisamatsu T,Suzuki K,Sakakibara S,et al. Antitumor spectrum of a new anthracycline, (2" R)-4'-O-tetrahydropyranyladriamycin,and effect on the cellu far immune response in mice[J]. Jpn J Cancer Res (Gann),1985, 76:1008—1020.
4Kunimoto S, Miura K, Umezawa K, et al. Cellular uptake and efflux and cytostatic activity of 4'-O-Tetrahydropyranyladriamycin in adriamycin-sensitive and resistant tumor cell lines[J]. J Antibiotics, 1984,37:1697—1702.
5Tsuruo T,Iida H,Tsukagoshi S,et al. 4'-O-tetrahydropyranyladriamycin as a potential new antitumor agent[J]. Cancer Research, 1982,42: 1462—1467.
6Kunimoto S,Miura K,Takahashi Y,et al. Rapid uptake by cultured tumor cells and intracellular behavior of 4'-O-tetrahydropyranyladriamycin[J]. J Antibiotics, 1983,36: 312—317.
7刀根弘井口博吏藤垣正夫 etal.新抗肿瘤性抗生物质（2”R）—4''—O—tertrahydropyranyladriamycinのうツトにおける生体内动态.单回投与试验[J].Jpn J Antibiotics,1986,39:612-612.
8刀根弘.井口博吏庄村知子 et al.新抗肿瘤性抗生物质（2”R）—4''—O—tetrahydropyranyladriamycinのうツトにおける生体内动态.反复投与试验[J].Jpn J Antibiotics,1986,39:629-629.
9Kurebe M,Sasaki H, Niizato T,et al. Toxicological studies on (2"R)-4'-O-tetrahydropyranyladriamycin,a new antitumor antibiotic. Its acute toxicity in rats[J]. Jpn J Antibiot, 1986, 39 (1):259—263.
10刀根弘白井正孝尾上房代 etal.新抗肿瘤性抗生物质（2”R）—4''—O—tetrahydropyranyladriamycinの毒性学研究マゥスにおける急性毒性试验[J].Jpn J Antibiotics,1986,39:250-250.